Taken together, these data suggest that miR-181c can attenuate wnt/β-catenin signaling, partially via RPN2, uncovering the existence of the miR-181c/RPN2/wnt pathway axis in GBM development and progression. The gene discussed is RPN2; the disease is glioblastoma.